Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.6152W HIGH $24.23
Volume
8.80 K
Value Traded
4.24 M
Short % Float
1.33%
-16.25%Week
-40%1 Month
+4.12%3 Month
-18.93%6 Month
-95.06%5 Year
-95.06%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
8.77 M
EPS (TTM)
3.20
P/E Ratio
1.66
Ent. Value
6.17 M
Total Shares
1.65 M
Float Shares
740.00 K
Insiders
55.36%
Institutions
0.08%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ADVB Catalyst Timeline
Dated clinical, regulatory and corporate events for Advanced Biomed Inc.
Past FDA Catalysts and PDUFA Decisions
How ADVB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Advanced Biomed Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every ADVB program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ADVB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ADVB for Q2 2026. | ||||
ADVB Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ADVB ranks across every disease it competes in
Competitive Position is a premium feature
See how ADVB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialADVB News
ADVB▼ -10.7%on this news
Advanced Biomed Inc. Announces 1 for 20 Share Consolidation
Advanced Biomed Inc. announced a 1 for 20 reverse stock split effective February 20, 2026. This decision was made to meet Nasdaq's minimum bid price requirement of $1.00 per share. The total issued shares will decrease from approximately 27 million to about 1.36 million, while the authorized shares remain unchanged. The company specializes in advanced biomedical technologies for cancer detection.
Read more →ADVBAdvanced Biomed Inc. Announces 120‑Case Feasibility Study with Chi‑Mei Medical Center to Validate A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery
Advanced Biomed Inc. has announced a collaboration with Chi-Mei Medical Center to conduct a 120-case feasibility study aimed at validating its A+PerfusC platform for precision medicine. The study will assess the predictive accuracy of drug sensitivity results from circulating tumor cells against actual patient outcomes. Results are expected to inform future clinical validation studies and support the platform's use in treatment decision-making.
Read more →ADVBAdvanced Biomed Inc. Announces Disposal of its Hong Kong Subsidiary
Advanced Biomed Inc. announced the sale of its Hong Kong subsidiary for $23,000 to Wei Ha Hui. This decision aims to centralize clinical trials in Taiwan, aligning with evolving regulatory requirements in China. The transaction includes the transfer of all intellectual property from the Hong Kong subsidiary. CEO Dr. Yi Lu emphasized the strategic realignment for accelerated product development.
Read more →ADVB▼ -17.2%on this news
Advanced Biomed Inc. Announces Launch of A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery
Advanced Biomed Inc. has launched the A+PerfusC™ system, an integrated perfusion 3D cell culture platform designed to replicate human physiological conditions. This innovative incubator supports continuous culture for up to 12 days, improving cell viability and drug response predictability. The company aims to scale this technology for high-throughput applications in personalized medicine and drug discovery.
Read more →ADVBPURCHASE AGREEMENT THIS PURCHASE AGREEMENT (this " Agreement "), dated as of
Advanced Biomed, Inc. has entered into a purchase agreement with Helena Global Investment Opportunities I Ltd. to sell up to $25 million worth of common stock. The agreement outlines specific terms, including the issuance and sale processes, which will comply with the Securities Act of 1933. The listing of the stock on Nasdaq adds legitimacy to this funding opportunity for the company.
Read more →ADVBAdvanced Biomed Inc. Announces Closing Of US$6.56 Million Initial Public Offering
Advanced Biomed Inc. has successfully closed its initial public offering, raising $6.56 million by offering 1,640,000 shares at $4.00 each. The shares commenced trading on the Nasdaq Capital Market under the ticker ADVB. The funds will be allocated to clinical research, marketing, and general working capital to enhance their cancer diagnostic technologies.
Read more →ADVBAdvanced Biomed Inc. Announces Pricing of Initial Public Offering
Advanced Biomed Inc. announced the pricing of its initial public offering (IPO) at $4.00 per share, totaling 1,640,000 shares. The company anticipates gross proceeds of approximately $6.56 million, which will be directed towards clinical research and market expansion. The shares will be listed on the Nasdaq under the ticker symbol 'ADVB'. Trading is expected to commence on March 6, 2025, pending customary closing conditions.
Read more →About Advanced Biomed Inc.
Headquarters401 RYLAND ST, RENO, NV, 89502
BIOPHARMAWATCH ELITE PLUS
Trade the next ADVB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime